Overall, the ex vivo tumor culture data demonstrate that blockade of PSGL-1 offers the potential to provide clinical benefits to cancer patients in monotherapy due to reprogramming the macrophage infiltrate residing in the tumor bed and thus overcoming the local immunosuppressive milieu. Here, SELPLG is linked to cancer.